Abstract
We report the results of treatment with MACOP-B in 11 young patients with low grade lymphoma (LGL). Complete remission was obtained in 4 (57%) and partial remission in 3 (42.8%) of 7 evaluable patients. However, this aggressive chemotherapy has not offered any advantage because of an unacceptably high treatment-related morbidity and mortality (17%). Serious infection during neutropenia was the most common complication.
Publication types
-
Case Reports
-
Clinical Trial
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bleomycin / adverse effects
-
Bleomycin / therapeutic use
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Female
-
Granulocytes / drug effects
-
Humans
-
Infections / etiology
-
Leucovorin / adverse effects
-
Leucovorin / therapeutic use
-
Lymphoma / drug therapy*
-
Lymphoma / mortality
-
Lymphoma / pathology
-
Male
-
Methotrexate / adverse effects
-
Methotrexate / therapeutic use
-
Middle Aged
-
Prednisone / adverse effects
-
Prednisone / therapeutic use
-
Remission Induction
-
Survival Analysis
-
Vincristine / adverse effects
-
Vincristine / therapeutic use
Substances
-
Bleomycin
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Leucovorin
-
Prednisone
-
Methotrexate